KREBSBIO · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 0/100 — Quality 0 · Momentum 0
| Share price | ₹54.30 |
| Market cap | ₹120 Cr |
| P/B ratio | -0.7 |
| ROE | -78.5% |
| ROCE | -19.6% |
| Book value | ₹-75.83 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹24 Cr | ₹-17 Cr | -50.0% |
| 2025 | ₹43 Cr | ₹-27 Cr | -50.1% |
| 2024 | ₹50 Cr | ₹-20 Cr | -30.7% |
| 2023 | ₹52 Cr | ₹-25 Cr | -42.1% |
| 2022 | — | — | — |
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applicatio